Cara Therapeutics | CARA - Operating Expenses


Cara Therapeutics reported $7.05M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.57M 450K Sep/2026
Alterity Therapeutics Limited AUD 8.67M 893.38K Dec/2025
Cara Therapeutics USD 7.05M 1.11M Mar/2026
Cassava Sciences USD 9.39M 1.78M Jun/2026
Chugai Pharma JPY 201.8B 21.07B Sep/2026
Cipla INR 63.61B 1.3B Sep/2026
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 11.44M 246K Jun/2026
CSL USD 5.7B 2.82B Dec/2025
Grifols EUR 1.99B 217.4M Dec/2025
Halozyme Therapeutics USD 198M 4.66M Sep/2026
J&J USD 18.93B 1.09B Sep/2026
Neurocrine Biosciences USD 779.7M 40.6M Sep/2026
Pacira USD 1.18B 995.96M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
RedHill Biopharma USD 5.51M 1.08M Jun/2024
Supernus Pharmaceuticals USD 1.06B 31.25M Sep/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025